Artiva Biotherapeutics, Inc.
ARTV
$10.79
-$0.09-0.83%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -17.65% | -15.78% | -29.06% | -23.21% | -19.12% |
| Total Depreciation and Amortization | 7.96% | 6.05% | 8.47% | 5.58% | 6.30% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 68.17% | 4.89% | 13.66% | -42.74% | -70.80% |
| Change in Net Operating Assets | 164.78% | 134.03% | 1,412.54% | -87.01% | -48,614.29% |
| Cash from Operations | 11.43% | -5.59% | -0.52% | -65.37% | -67.94% |
| Capital Expenditure | 60.66% | 52.64% | -557.81% | -525.00% | -127.37% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -18.83% | 48.43% | 1,924.94% | 112.93% | 1,123.22% |
| Cash from Investing | -16.75% | 53.61% | 1,760.46% | 112.46% | 1,465.75% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 63.64% | 0.00% | -3.03% | 15.79% | 57.69% |
| Issuance of Common Stock | 223,933.58% | -- | -100.00% | -- | 509.09% |
| Repurchase of Common Stock | 100.00% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -12,529.85% | -2.24% | 100.00% | 108.95% | 91.41% |
| Cash from Financing | 393,529.17% | -146.86% | -303.33% | -100.02% | 95.54% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 14,611.07% | 40.34% | 107.62% | -113.68% | 86.15% |